Previous close | 226.01 |
Open | 223.26 |
Bid | 227.46 x 800 |
Ask | 227.66 x 800 |
Day's range | 224.41 - 230.00 |
52-week range | 203.37 - 460.21 |
Volume | |
Avg. volume | 549,985 |
Market cap | 11.546B |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | 27.18 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WILMINGTON, Mass. & MACCLESFIELD, England, June 28, 2022--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park.
WILMINGTON, Mass. & GHENT, Belgium, June 23, 2022--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine program.
WILMINGTON, Mass., June 13, 2022--Charles River and ASC Therapeutics announce expanded relationship to scale manufacturing for a second generation gene therapy for hemophilia A.